Innate Pharma (IPHA) and the Institute for Follicular Lymphoma said Friday they have agreed to study the potential of the company's IPH6501 experimental therapy in follicular lymphoma, a type of blood cancer.
The company's ongoing phase 1/2 trial, which examines IPH6501 in relapsed/refractory non-hodgkin lymphoma, will now include patients with relapsed/refractory follicular lymphoma.
To support the inclusion of follicular lymphoma patients in the trial, the Institute for Follicular Lymphoma will initially invest $3 million into new shares of Innate.
The Institute for Follicular Lymphoma may invest an additional $4.9 million upon reaching certain milestones, the partners said.
Shares of Innate Pharma rose more than 12% in premarket activity.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。